Implications for a policy of initiating antiretroviral therapy in people diagnosed with human immunodeficiency virus: the CAPRA research programme

Ada Miltz,* Andrew N Phillips, Andrew Speakman, Valentina Cambiano, Alison Rodger and Fiona C Lampe

Research Department of Infection and Population Health, University College London, London, UK

*Corresponding author Ada.Miltz.11@ucl.ac.uk

Declared competing interests of authors: Andrew N Phillips has undertaken consultancy with GlaxoSmithKline Biologicals, Gilead Sciences, Inc., and AbbVie Inc. Alison Rodger has received unrestricted grant funding from Gilead Sciences, Inc. Six pharmaceutical companies (Abbott Laboratories, Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, Inc., Merck & Co, Inc., and Tibotec Pharmaceuticals, Ltd) have donated more than 20 antiretroviral drug formulations to the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Therapy (START) study. The University of Minnesota, the sponsor of START, receives royalties from the use of abacavir (Ziagen®, ViiV Healthcare UK Ltd), one of the HIV therapies that can be used in the START study. Valentina Cambiano reports personal fees from Merck Sharp & Dohme Ltd, outside the submitted work.

Published October 2017
DOI: 10.3310/pgfar05180
Plain English summary

In the UK, the human immunodeficiency virus (HIV) is mainly transmitted by sex without a condom. Without antiretroviral therapy (ART), HIV wipes out key immune cells called cluster of differentiation 4 (CD4) cells. In the past, the CD4 cell count was allowed to drop to a certain, still-safe, level before starting ART, in order to balance the risk of side effects. Recent studies have shown that ART also dramatically reduces the risk of HIV transmission to a sexual partner, and an alternative policy of treating everyone with HIV from the time of their diagnosis has been considered. In this programme of work we focused on men who have sex with men (MSM), and investigated if a change in treatment policy – to treat all MSM infected with HIV from the time of diagnosis – would be an efficient use of NHS resources given the increased use of drugs. From our findings, we estimated that the benefits (i.e. preventing future HIV transmission) are likely to be greater than the cost of increased drug use and, therefore, that a change in treatment policy is likely to be cost-effective among MSM. Following the completion of our programme of work, a large clinical trial investigating whether or not treating people with a higher CD4 cell counts versus treating people with lower but still safe CD4 cell counts [the Strategic Timing of Antiretroviral Therapy (START) trial] has more health benefits, found that individuals infected with HIV have health benefits from starting earlier ART. These findings support our conclusion that ART initiation in MSM diagnosed with HIV is likely to be cost-effective. The results from the START trial are not presented in this report in any detail because only a substudy of sexual behaviour among START participants was investigated as part of the Comprehensive Assessment of the Prevention Role of Antiretroviral therapy (CAPRA) grant. This report presents the results from our cost-effectiveness analysis and the studies used to inform this analysis.
Programme Grants for Applied Research

Criteria for inclusion in the Programme Grants for Applied Research journal
Reports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Programme Grants for Applied Research programme
The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.

The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm

This report
The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0608-10142. The contractual start date was in January 2010. The final report began editorial review in May 2016 and was accepted for publication in July 2017. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miltz et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Programme Grants for Applied Research Editor-in-Chief

Professor Paul Little  Professor of Primary Care Research, University of Southampton, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact:  journals.library@nihr.ac.uk